CytRx Corporation, a biopharmaceutical company, engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor.
Flawless balance sheet and overvalued.
Share Price & News
How has CytRx's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CX5P has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CX5P underperformed the German Biotechs industry which returned 5.3% over the past year.
Return vs Market: CX5P underperformed the German Market which returned 17.1% over the past year.
Price Volatility Vs. Market
How volatile is CytRx's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is CytRx undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CX5P's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CX5P's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CX5P is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: CX5P is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CX5P's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CX5P is good value based on its PB Ratio (0.6x) compared to the DE Biotechs industry average (3.4x).
How is CytRx forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CytRx has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine CytRx's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- CytRx competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has CytRx performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CX5P is currently unprofitable.
Growing Profit Margin: CX5P is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CX5P is unprofitable, but has reduced losses over the past 5 years at a rate of 24.7% per year.
Accelerating Growth: Unable to compare CX5P's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CX5P is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).
Return on Equity
High ROE: CX5P has a negative Return on Equity (-37.28%), as it is currently unprofitable.
How is CytRx's financial position?
Financial Position Analysis
Short Term Liabilities: CX5P's short term assets ($19.9M) exceed its short term liabilities ($1.9M).
Long Term Liabilities: CX5P has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: CX5P is debt free.
Reducing Debt: CX5P had no debt 5 years ago.
Inventory Level: CX5P has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if CX5P's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CX5P has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CX5P has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 58.9% each year.
What is CytRx's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CX5P's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CX5P's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CX5P's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CX5P's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CX5P's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Kriegsman (77yo)
Mr. Steven A. Kriegsman, also known as Steve, founded The Kriegsman Group in 1992 and serves as its President. Mr. Kriegsman also founded Kriegsman Capital Group LLC and has been its President since 1989. ...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD1.01M) is above average for companies of similar size in the German market ($USD425.50K).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
|Chairman of the Board & CEO||17.25yrs||US$1.01m||2.6% $239.1k|
|CFO & Treasurer||10.75yrs||US$500.00k||0.0022% $206.8|
|Senior Vice President||5.58yrs||US$302.00k||no data|
|President & COO||1.42yrs||no data||no data|
Experienced Management: CX5P's management team is seasoned and experienced (8.2 years average tenure).
|Chairman of the Board & CEO||17.25yrs||US$1.01m||2.6% $239.1k|
|Lead Director||2.67yrs||US$124.00k||0.0065% $597.6|
Experienced Board: CX5P's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.7%.
CytRx Corporation's company bio, employee growth, exchange listings and data sources
- Name: CytRx Corporation
- Ticker: CX5P
- Exchange: DB
- Founded: 1985
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$10.091m
- Listing Market Cap: US$9.193m
- Shares outstanding: 33.64m
- Website: https://www.cytrx.com
Number of Employees
- CytRx Corporation
- 11726 San Vicente Boulevard
- Suite 650
- Los Angeles
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CYTR||OTCPK (Pink Sheets LLC)||Yes||Common Stock||US||USD||Nov 1986|
|CX5P||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 1986|
|0I5R||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Nov 1986|
CytRx Corporation, a biopharmaceutical company, engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company’s lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides albumin companion diagnostic for cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/10/09 20:30|
|End of Day Share Price||2019/07/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.